The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.
Provider AI Strategy Moves From The IT Dept. To The C-Suite
What You Should Know: A new study from Bain & Company and KLAS Research shows US healthcare providers are accelerating spending on IT and software.